APA (7th ed.) Citation

D, S., A, F., M, D., NJ, E., F, R., C, M., . . . AVS, H. (2026). Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults. Wellcome open research, 9, 734. https://doi.org/10.12688/wellcomeopenres.22900.2

Chicago Style (17th ed.) Citation

D, Silman, et al. "Phase I/IIa Study to Assess the Safety, Immunogenicity and Efficacy of ChAdOx1-MVA Vectored Vaccines Expressing a Novel Liver-stage Malaria Dual Antigen LS2 by Sporozoite Challenge in Malaria-naïve Adults." Wellcome Open Research 9 (2026): 734. https://doi.org/10.12688/wellcomeopenres.22900.2.

MLA (9th ed.) Citation

D, Silman, et al. "Phase I/IIa Study to Assess the Safety, Immunogenicity and Efficacy of ChAdOx1-MVA Vectored Vaccines Expressing a Novel Liver-stage Malaria Dual Antigen LS2 by Sporozoite Challenge in Malaria-naïve Adults." Wellcome Open Research, vol. 9, 2026, p. 734, https://doi.org/10.12688/wellcomeopenres.22900.2.